Taking endocrine therapy (ET) for 5 years after breast cancer diagnosis has shown to greatly reduce future recurrence and extend survival in women with hormone-sensitive tumors. In spite of these benefits, as many as 50% of women prescribed ET fail to comply with the medication. In such cases, the survival benefits of ET become demonstrably diminished, if not all together negated. Unfortunately, a strong risk factor believed to contribute to treatment non-compliance is advanced age. Low compliance with adjuvant ET within the geriatric population is particularly troubling, given that the negative clinical consequences associated with non-compliance may necessitate further treatment which can be particularly complex in the elderly population.
|Effective start/end date||7/1/15 → 6/30/17|
- American Society for Therapeutic Radiology and Oncology (ASTRO)